A type I interferon signature characterizes chronic antibody‐mediated rejection in kidney transplantation
Chronic antibody‐mediated rejection (CAMR) represents the main cause of kidney graft loss. To uncover the molecular mechanisms underlying this condition, we characterized the molecular signature of peripheral blood mononuclear cells (PBMCs) and, separately, of CD4 + T lymphocytes isolated from CAMR patients, compared to kidney transplant recipients with normal graft function and histology. We enrolled 29 patients with biopsy‐proven CAMR, 29 stable transplant recipients (controls), and 8 transplant recipients with clinical and histological evidence of interstitial fibrosis/tubular atrophy. Messenger RNA and microRNA profiling of PBMCs and CD4 + T lymphocytes was performed using Agilent microarrays in eight randomly selected patients per group from CAMR and control subjects. Results were evaluated statistically and by functional pathway analysis (Ingenuity Pathway Analysis) and validated in the remaining subjects. In PBMCs, 45 genes were differentially expressed between the two groups, most of which were up‐regulated in CAMR and were involved in type I interferon signalling. In the same patients, 16 microRNAs were down‐regulated in CAMR subjects compared to controls: four were predicted modulators of six mRNAs identified in the transcriptional analysis. In silico functional analysis supported the involvement of type I interferon signalling. To further confirm this result, we investigated the transcriptomic profiles of CD4 + T lymphocytes in an independent group of patients, observing that the activation of type I interferon signalling was a specific hallmark of CAMR. In addition, in CAMR patients, we detected a reduction of circulating BDCA2 + dendritic cells, the natural type I interferon‐producing cells, and their recruitment into the graft along with increased expression of MXA, a type I interferon‐induced protein, at the tubulointerstitial and vascular level. Finally, interferon alpha mRNA expression was significantly increased in CAMR compared to control biopsies. We conclude that type I interferon signalling may represent the molecular signature of CAMR. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:237 |
|---|---|
| Enthalten in: |
The journal of pathology - 237(2015), 1, Seite 72-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rascio, Federica [VerfasserIn] |
|---|
| Links: |
Volltext |
|---|
| doi: |
10.1002/path.4553 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1963520815 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1963520815 | ||
| 003 | DE-627 | ||
| 005 | 20230714161207.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1002/path.4553 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1963520815 | ||
| 035 | |a (DE-599)GBVOLC1963520815 | ||
| 035 | |a (PRQ)g2263-b4bd2dd3c98d8afd3b1b104ccbd4372d14a8db23f63e96b797a6ceaf398eafd3 | ||
| 035 | |a (KEY)0017922120150000237000100072typeiinterferonsignaturecharacterizeschronicantibo | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Rascio, Federica |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A type I interferon signature characterizes chronic antibody‐mediated rejection in kidney transplantation |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Chronic antibody‐mediated rejection (CAMR) represents the main cause of kidney graft loss. To uncover the molecular mechanisms underlying this condition, we characterized the molecular signature of peripheral blood mononuclear cells (PBMCs) and, separately, of CD4 + T lymphocytes isolated from CAMR patients, compared to kidney transplant recipients with normal graft function and histology. We enrolled 29 patients with biopsy‐proven CAMR, 29 stable transplant recipients (controls), and 8 transplant recipients with clinical and histological evidence of interstitial fibrosis/tubular atrophy. Messenger RNA and microRNA profiling of PBMCs and CD4 + T lymphocytes was performed using Agilent microarrays in eight randomly selected patients per group from CAMR and control subjects. Results were evaluated statistically and by functional pathway analysis (Ingenuity Pathway Analysis) and validated in the remaining subjects. In PBMCs, 45 genes were differentially expressed between the two groups, most of which were up‐regulated in CAMR and were involved in type I interferon signalling. In the same patients, 16 microRNAs were down‐regulated in CAMR subjects compared to controls: four were predicted modulators of six mRNAs identified in the transcriptional analysis. In silico functional analysis supported the involvement of type I interferon signalling. To further confirm this result, we investigated the transcriptomic profiles of CD4 + T lymphocytes in an independent group of patients, observing that the activation of type I interferon signalling was a specific hallmark of CAMR. In addition, in CAMR patients, we detected a reduction of circulating BDCA2 + dendritic cells, the natural type I interferon‐producing cells, and their recruitment into the graft along with increased expression of MXA, a type I interferon‐induced protein, at the tubulointerstitial and vascular level. Finally, interferon alpha mRNA expression was significantly increased in CAMR compared to control biopsies. We conclude that type I interferon signalling may represent the molecular signature of CAMR. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. | ||
| 540 | |a © COPYRIGHT 2015 Wiley Subscription Services, Inc. | ||
| 650 | 4 | |a immunology | |
| 650 | 4 | |a RNA | |
| 650 | 4 | |a chronic antibody‐mediated rejection | |
| 650 | 4 | |a profiling | |
| 650 | 4 | |a T lymphocytes | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a microRNA | |
| 650 | 4 | |a type I interferon | |
| 650 | 4 | |a messenger | |
| 650 | 4 | |a peripheral blood mononuclear cells | |
| 650 | 4 | |a and | |
| 650 | 4 | |a Kidney Transplantation - adverse effects | |
| 650 | 4 | |a Kidney - immunology | |
| 650 | 4 | |a Kidney - surgery | |
| 650 | 4 | |a MicroRNAs - metabolism | |
| 650 | 4 | |a CD4-Positive T-Lymphocytes - metabolism | |
| 650 | 4 | |a Graft Rejection - blood | |
| 650 | 4 | |a Interferon Type I - immunology | |
| 650 | 4 | |a Biological Markers - metabolism | |
| 650 | 4 | |a Interferon Type I - metabolism | |
| 650 | 4 | |a Graft Rejection - immunology | |
| 650 | 4 | |a Leukocytes, Mononuclear - immunology | |
| 650 | 4 | |a Gene Expression Profiling - methods | |
| 650 | 4 | |a Kidney - metabolism | |
| 650 | 4 | |a RNA, Messenger - metabolism | |
| 650 | 4 | |a Kidney - pathology | |
| 650 | 4 | |a Interferon Type I - genetics | |
| 650 | 4 | |a CD4-Positive T-Lymphocytes - immunology | |
| 650 | 4 | |a Graft Rejection - genetics | |
| 650 | 4 | |a Leukocytes, Mononuclear - metabolism | |
| 650 | 4 | |a Dendritic cells | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Transplantation | |
| 650 | 4 | |a Analysis | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a MicroRNA | |
| 650 | 4 | |a Kidneys | |
| 650 | 4 | |a Interferon alpha | |
| 650 | 4 | |a Viral antibodies | |
| 650 | 4 | |a Organ transplant recipients | |
| 650 | 4 | |a Biological response modifiers | |
| 700 | 1 | |a Pontrelli, Paola |4 oth | |
| 700 | 1 | |a Accetturo, Matteo |4 oth | |
| 700 | 1 | |a Oranger, Annarita |4 oth | |
| 700 | 1 | |a Gigante, Margherita |4 oth | |
| 700 | 1 | |a Castellano, Giuseppe |4 oth | |
| 700 | 1 | |a Gigante, Maddalena |4 oth | |
| 700 | 1 | |a Zito, Anna |4 oth | |
| 700 | 1 | |a Zaza, Gianluigi |4 oth | |
| 700 | 1 | |a Lupo, Antonio |4 oth | |
| 700 | 1 | |a Ranieri, Elena |4 oth | |
| 700 | 1 | |a Stallone, Giovanni |4 oth | |
| 700 | 1 | |a Gesualdo, Loreto |4 oth | |
| 700 | 1 | |a Grandaliano, Giuseppe |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of pathology |d Chichester [u.a.] : Wiley, 1969 |g 237(2015), 1, Seite 72-84 |w (DE-627)129079103 |w (DE-600)3119-7 |w (DE-576)014411725 |x 0022-3417 |7 nnns |
| 773 | 1 | 8 | |g volume:237 |g year:2015 |g number:1 |g pages:72-84 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1002/path.4553 |3 Volltext |
| 856 | 4 | 2 | |u http://onlinelibrary.wiley.com/doi/10.1002/path.4553/abstract |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25925804 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1702086255 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2141 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4306 | ||
| 951 | |a AR | ||
| 952 | |d 237 |j 2015 |e 1 |h 72-84 | ||